Kite Pharma, Inc. (Kite) is a privately held development stage biotechnology company engaged in the development of novel cancer immunotherapeutic products with focus on engineered autologous T cell therapy (eACT), designed at restoring the patient's immune system to recognize and eradicate tumors. In partnership with the National Cancer Institute (NCI) Surgery Branch, Kite is advancing a pipeline of proprietary eACT product candidates directed to a wide range of cancer indications. These novel personalized and targeted immunotherapies, which capitalize on the selectivity and potency of immune cells, are aimed at providing significant and durable clinical benefit regardless of tumor origin, disease stage, and prior treatments. In addition, the company is advancing a novel therapeutic cancer vaccine aimed to trigger potent and specific immunity against multiple epithelial cancers, which has the potential to complement its eACT programs.
Kite's management team has a proven track record of building successful biotechnology companies and developing cutting edge immunotherapies and oncology treatments. The company's Scientific Advisory Board is comprised of leaders who have discovered and guided the advancement of key novel immunotherapies.